Skip to main content
Clinical Trials/NCT05132881
NCT05132881Active, not recruitingNot Applicable

Effect of Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS) on Anxiety and Brain Function in Distressed Healthcare Professionals

Thomas Jefferson University2 sites in 1 country90 target enrollmentStarted: April 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
90
Locations
2
Primary Endpoint
Galvanic Skin Resistance (GSR) for Active and Waitlist

Study Overview

Brief Summary

The purpose of this research is to measure alterations in anxiety and brain activity associated with the use of an approved health device called Transauricular Vagal Nerve Stimulation (TaVNS) in distressed persons who work in a health care and distressed healthcare workers in the the Philadelphia, PA region. The Investigators will be using functional magnetic resonance imaging (or fMRI) to measure changes in each subject's brain function during the use of VNS. This study is designed to allow researchers to understand the changes in cerebral (brain) activity that occur when a subject uses VNS. Thus, the primary goal of the proposed study is to evaluate the ability of the TaVNS system to reduce distress and change neurophysiology among health care providers.

The Investigators, hypothesize that using the TaVNS device will help reduce distress in individuals.

In order to understand the mechanisms of change that occur while using the VNS study, the Investigators have added a substudy of participants who do not experience high levels of distress to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device.

In addition to the primary aims of the overalll study to assess distress in workers while enrolled in a TaVNS program, a subgroup of 50 subjects will undergo functional magnetic resonance imaging (fMRI) while using the VNS device to assess the changes in the brain including neurophysiological effects of TaVNS.

The goal of this substudy is to observe the changes in the brain while using the TaVNS earbuds in the MRI to increase our understanding of the mechanisms and processing involved while using TaVNS. In this substudy, which is amendment version 3.0, the investigators have increased the number of persons to include 50 subjects who will use the device in the MRI to evaluate the neural processes and cerebral blood flow while using TaVNS.

Detailed Description

A total of up to 90 distressed persons who work in health care and health care providers in the Philadelphia, PA region, will be screened for this study. From that group, the researchers plan to enroll enough subjects to have 80 fully complete the study. The 90 screened subjects will allow for screen failures and subjects who withdraw early from the study. All subjects will receive an initial evaluation using symptom questionnaires (these will include the Global Severity Index of the Brief Symptom Inventory-18 which is the primary outcome, and secondary outcomes as measured by the Maslach Burnout Scale, GAD-7 (anxiety), PHQ-9 (depression), the Connor Davidson Resilience Scale-25 (CD-RISC), and the Insomnia Severity Index (ISI) and physiological measures that will consist of heart rate variability (HRV) and galvanic skin resistance (GSR). Subjects will then be randomized to either the 3 month TaVNS program or the 3 month waitlist group. At one month, subjects will receive a follow up request to complete the same questionnaires as in the initial evaluation for an interim evaluation. Then after receiving the TaVNS program or being in the waitlist control group for 3 months, the subjects will have a repeat of the questionnaires and physiological testing. Subjects in the waitlist group will then be provided the TaVNS program to be used for 3 months. This group will be asked to complete one final set of symptom questionnaires at the completion of using the TaVNS program.

Two subgroups will be included in fMRI scans performed during the initial evaluation period (pre) and at 3 months (post). Subgroup I of 30 subjects (15 in TaVNS group and 15 in waitlist control) will undergo fMRI scans that will include structural imaging and functional imaging with Blood Oxygen Level Dependent Imaging (BOLD) scan and arterial spin labeling (ASL) scans. Specifically, during the ASL scans (each approximately 5 minutes long), a script of the subject's most distressing recollection(s) will be read from an audio file script while each subject is in the MRI scanner. Changes in brain function will be compared between the stress script and a neutral script (that describes a typical morning waking up). This same imaging protocol, which takes a total of about 45 minutes, will be performed initially and then after the 3 month TaVNS program or the waitlist period. All scans will be co-registered and comparable slices of the cerebral cortex will be examined.

Subgroup II will consist of 10 study subjects all receiving the TaVNS program who will undergo fMRI initially and then again at 3 months. This group will be scanned while wearing the TaVNS system (a special one that can be used in the MRI environment) and the fMRI will be used to evaluate the direct effects of the TaVNS while turned on and off in the scanner. The imaging protocol will take a total of about 45 minutes. In addition to the 10 study subjects, the researchers will also plan to recruit 10 healthy controls with no reports of psychological distress (i.e. less than 2 on the SUDS). These 10 healthy controls will have the TaVNS placed while receiving two fMRI scans approximately 3 months apart. These control subjects will be used to compare the subgroup of study subjects to ensure that any changes are not associated with test-retest effects.

The subgroups will be filled with eligible and interested subjects. If the subject is interested and is able to undergo fMRI scanning, the subject will be placed in Subgroup I until enrollment is filled and then subsequently subjects will be enrolled into Subgroup II until enrollment is filled. Any eligible subject that is unwilling or unable to undergo fMRI scanning will be placed in the general, non-scanning group. Once the two subgroups are filled, any remaining eligible subjects will be placed in the general, non-scanning group.

Substudy:

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Crossover
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy male and female persons who work in health care and health care workers (all races and ethnicity) >21 years of age
  • All subjects must have a smartphone device that can be used in conjunction the Neuvana 2.0
  • Drug-free from medications that may affect brain physiology such that the imaging results will not be useful as determined by the PI.
  • Able to understand and provide signed informed consent. Available and willing to be followed -up according to study protocol
  • Female subjects of childbearing potential have a negative pregnancy test
  • Subjects have no significant medical neurological or psychological disorders
  • Stable health problems that should have no substantial effect on cerebral blood flow will be allowed (i.e. controlled hypertension, medication controlled diabetes).
  • Current medications and supplements will be reviewed by the Principal Investigator or a designated physician or health practitioner. Subjects may take medications or supplements but should be on a stable dose regimen for at least 3 months. For those receiving TaVNS program, it is preferable that subjects remain on that dose for the full TaVNS program period (with the exception of having an adverse reaction in which the medication or supplement must be stopped).
  • PI will evaluate each subject for any potential medical issues that might be a problem and will consult with the subject's primary care provider if there are any questions about it.
  • Additional Inclusion Criteria for the TaVNS program for Distressed Workers
  • Distress scored as at least a 6 or greater on the SUDS distress level from 1 to
  • Distressing recollection(s) that causes physiological reactivity (i.e., increased heart rate and/or increased skin conductance level - SCL), as described above.
  • Healthy control with no distress or other exclusion criteria

Exclusion Criteria

  • Any medical conditions that may interfere with cerebral blood flow as determined by the PI.
  • Currently taking medication that might affect cerebral blood flow as per the P.I. (i.e. antidepressants, antipsychotics, anxiolytics, benzodiazepines, sedatives, anti-seizure medications, but with the exception of those described above)
  • Subject is unable or unwilling to lie still in the scanner (i.e. due to claustrophobia or weight)
  • Subject has metal in their body or other reason that they cannot undergo magnetic resonance imaging.
  • Previous brain surgery or intracranial abnormalities they may complicate interpretation of the brain scans (e.g., stroke, tumor, vascular abnormality).
  • Pregnancy or breastfeeding
  • Concurrent participation in another research protocol that might affect the outcome of this study.
  • Use of a defibrillator or pacemaker or other implanted or metallic electronic device. Doing so could cause electric shock, burns, electrical interference, or death.
  • History of Seizures
  • Temporomandibular Joint Disorder, Bell's Palsy, impaired cranial nerve function, or facial pain.

Outcomes

Primary Outcomes

Galvanic Skin Resistance (GSR) for Active and Waitlist

Time Frame: Change from baseline and after using the TaVNS System approximately 90 days (~3 months)]

To measure changes in sweat gland activity, which reflect the intensity of participants' emotional state

Functional magnetic resonance imaging (fMRI) in Active and Waitlist Groups

Time Frame: Change from baseline and after using the TaVNS system approximately 90 days (~3 months)] .

This scan will be used to assess functional connectivity, tractography, and brain volume

Subjective Units of Distress Survey

Time Frame: Evaluate at baseline to evaluate distress for healthy controls in Group III

The Subjective Units of Distress Survey (SUDS) is a way for participants to communicate how much distress they are currently feeling using a 0 to 10 scale with zero corresponding to a relaxed state without distress and ten corresponding to extreme distress filled with panic, tension, fear, and anxiety.

Blood Oxygen Level Dependent Imaging scan in Active and Waitlist Groups

Time Frame: Change from baseline and after using the TaVNS System approximately 90 days (~3 months)]

Blood Oxygen Level Dependent Imaging (BOLD) scan fMRI analysis, used to observe different areas of the brain or other organs, which are found to be active at any given time.

Heart Rate Variability for Active and Waitlist

Time Frame: Change from baseline and after using the TaVNS system approximately 90 days (~3 months)] .

Heart rate variability (HRV) is the physiological phenomenon of the variation in the time interval between consecutive heartbeats in milliseconds.

Functional magnetic resonance imaging (fMRI) in all groups

Time Frame: Subjects will be evaluated at baseline

This scan will be used to assess functional connectivity, tractography, and brain volume

Blood Oxygen Level Dependent Imaging scan in all groups

Time Frame: Subject will be evaluated at baseline

Blood Oxygen Level Dependent Imaging (BOLD) scan analysis, used to observe different areas of the brain or other organs, which are found to be active at any given time.

Arterial spin labeling scan in all groups

Time Frame: Subjects will be evaluated at baseline

Arterial spin labeling (ASL) scan fMRI analysis, used to quantify cerebral blood perfusion by labelling blood water as it flows throughout the brain.

Arterial spin labeling scan in Active and Waitlist Groups

Time Frame: Change from baseline and after using the TaVNS System approximately 90 days (~3 months)]

Arterial spin labeling (ASL) scan fMRI analysis used to quantify cerebral blood perfusion by labelling blood water as it flows throughout the brain.

Secondary Outcomes

  • Patient Health Questionnaire(Subjects will be evaluated at approximately three months follow up with questionnaires.)
  • Connor Davidson Resilience Scale-25 (CD-RISC)(Subjects will be evaluated at baseline with questionnaires.)
  • Patient Health Questionnaire (PHQ-9)(depression)(Subjects will be evaluated at baseline and approximately six months follow up with questionnaires.)
  • General Anxiety Disorder(Subjects will be evaluated at baseline and approximately six months follow up with questionnaires.)
  • Connor Davidson Resilience Scale-25(Subjects will be evaluated at baseline and approximately six months follow up with questionnaires.)
  • Global Severity Index of the Brief Symptom Inventory-18(Subjects will be evaluated at six months after using the TaVNS system.)
  • The Maslach Burnout Scale(Subjects will be evaluated approximately six months follow up with questionnaires.)
  • Insomnia Severity Index(Subjects will be evaluated at baseline and approximately six months follow up with questionnaires.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Andrew Newberg

Professor, Department of Integrative Medicine and Nutritional Sciences; Professor, Department of Radiology

Thomas Jefferson University

Study Sites (2)

Loading locations...

Similar Trials